type InlinePart =
  | string
  | Readonly<{
      emphasis?: "em" | "strong";
      href?: string;
      text: string;
    }>;

type InlineContent = readonly InlinePart[];

type ResearchBlock =
  | Readonly<{ content: InlineContent; type: "paragraph" }>
  | Readonly<{ level: 2 | 3; text: string; type: "heading" }>
  | Readonly<{
      items: readonly InlineContent[];
      style: "ordered" | "unordered";
      type: "list";
    }>
  | Readonly<{
      content: InlineContent;
      label: string;
      type: "callout";
    }>
  | Readonly<{
      caption: string;
      columns: readonly string[];
      rows: readonly (readonly InlineContent[])[];
      type: "table";
    }>;

function paragraph(...content: InlinePart[]): ResearchBlock {
  return { type: "paragraph", content };
}

function heading(text: string, level: 2 | 3 = 2): ResearchBlock {
  return { type: "heading", level, text };
}

function item(...content: InlinePart[]): InlineContent {
  return content;
}

function unordered(...items: InlineContent[]): ResearchBlock {
  return { type: "list", style: "unordered", items };
}

function ordered(...items: InlineContent[]): ResearchBlock {
  return { type: "list", style: "ordered", items };
}

function callout(label: string, ...content: InlinePart[]): ResearchBlock {
  return { type: "callout", label, content };
}

function table(
  caption: string,
  columns: readonly string[],
  ...rows: readonly (readonly InlineContent[])[]
): ResearchBlock {
  return { type: "table", caption, columns, rows };
}

function strong(text: string): InlinePart {
  return { text, emphasis: "strong" };
}

function link(text: string, href: string): InlinePart {
  return { text, href };
}

export const SLEEP_HEALTH_SOURCES = {
  magnesiumOds: {
    title: "Magnesium: Fact Sheet for Health Professionals",
    publication: "NIH Office of Dietary Supplements",
    year: 2026,
    url: "https://ods.od.nih.gov/factsheets/Magnesium-HealthProfessional/",
    note:
      "Current U.S. reference for magnesium forms, absorption, food sources, elemental labeling, interactions, kidney risk, and the supplemental upper limit.",
  },
  magnesiumMeta2021: {
    title:
      "Oral magnesium supplementation for insomnia in older adults: a systematic review and meta-analysis",
    publication: "BMC Complementary Medicine and Therapies",
    year: 2021,
    url: "https://pubmed.ncbi.nlm.nih.gov/33865376/",
    note:
      "A three-trial review of 151 older adults that found a possible sleep-latency signal but rated the evidence low to very low quality.",
  },
  magnesiumReview2022: {
    title:
      "The association between magnesium status and sleep quality: a systematic review",
    publication: "Biological Trace Element Research",
    year: 2022,
    url: "https://pubmed.ncbi.nlm.nih.gov/35184264/",
    note:
      "A synthesis finding observational associations but contradictory randomized evidence and substantial variation among studies.",
  },
  magnesiumThreonate2024: {
    title:
      "Magnesium L-threonate improves sleep quality and daytime functioning in adults with self-reported sleep problems",
    publication: "Sleep Medicine: X",
    year: 2024,
    url: "https://pubmed.ncbi.nlm.nih.gov/39252819/",
    note:
      "A randomized trial with subjective outcomes and industry relationships that offers a form-specific signal rather than a head-to-head form comparison.",
  },
  magnesiumBisglycinate2025: {
    title:
      "Magnesium bisglycinate supplementation in adults with poor sleep: a randomized controlled trial",
    publication: "Nutrients",
    year: 2025,
    url: "https://pubmed.ncbi.nlm.nih.gov/40918053/",
    note:
      "A 155-person trial reporting a small four-week insomnia-score difference and calling for objective sleep measurements and replication.",
  },
  fdaSupplements: {
    title: "Information for Consumers on Using Dietary Supplements",
    publication: "U.S. Food and Drug Administration",
    year: 2024,
    url: "https://www.fda.gov/food/dietary-supplements/information-consumers-using-dietary-supplements",
    note:
      "Official guidance explaining that FDA does not approve dietary supplements for safety and effectiveness before they reach the market.",
  },
  uspVerification: {
    title: "Dietary Supplements Verification Program",
    publication: "U.S. Pharmacopeia",
    year: 2026,
    url: "https://www.usp.org/verification-services/dietary-supplements-verification-program",
    note:
      "Describes independent identity, potency, contaminant, manufacturing, and off-the-shelf checks while clarifying that quality verification is not efficacy proof.",
  },
  lTheanineMeta2025: {
    title: "The effects of L-theanine consumption on sleep outcomes",
    publication: "Sleep Medicine Reviews",
    year: 2025,
    url: "https://pubmed.ncbi.nlm.nih.gov/40056718/",
    note:
      "A 19-article, 897-participant synthesis reporting modest subjective signals while emphasizing mixed products and uncertain optimal use.",
  },
  lTheanineReview2026: {
    title:
      "L-theanine as a sleep aid: a systematic review of standalone interventions",
    publication: "Journal of Nutrition",
    year: 2026,
    url: "https://pubmed.ncbi.nlm.nih.gov/41176609/",
    note:
      "A review of 13 standalone trials that found promising signals but has tobacco-industry research affiliations requiring explicit context.",
  },
  valerianUmbrella2024: {
    title: "Does valerian work for insomnia? An umbrella review of the evidence",
    publication: "European Neuropsychopharmacology",
    year: 2024,
    url: "https://pubmed.ncbi.nlm.nih.gov/38359657/",
    note:
      "An eight-review umbrella synthesis finding no demonstrated efficacy for insomnia despite possible subjective sleep-quality improvement.",
  },
  nccihValerian: {
    title: "Valerian: Usefulness and Safety",
    publication: "National Center for Complementary and Integrative Health",
    year: 2026,
    url: "https://www.nccih.nih.gov/health/valerian",
    note:
      "Current federal summary of valerian's historical use, uncertain efficacy, short-term safety evidence, interactions, and unknown long-term safety.",
  },
  californiaPoppyEma: {
    title: "Eschscholziae herba: European Union herbal assessment",
    publication: "European Medicines Agency",
    year: 2026,
    url: "https://www.ema.europa.eu/en/medicines/herbal/eschscholziae-herba",
    note:
      "Regulatory assessment distinguishing traditional use of California poppy aerial parts from clinical proof of efficacy.",
  },
  californiaValerianTrial2026: {
    title:
      "Combined Eschscholtzia californica and Valeriana officinalis extracts for insomnia associated with anxiety",
    publication: "Sleep Epidemiology",
    year: 2026,
    url: "https://doi.org/10.1016/j.sleepe.2026.100138",
    note:
      "A randomized placebo-controlled trial of a fixed two-herb product that cannot isolate either herb or establish equivalence across preparations.",
  },
  plantExtractSleepReview2020: {
    title:
      "Plant extracts for sleep disturbances: a systematic review of clinical evidence",
    publication: "Nutrients",
    year: 2020,
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC7191368/",
    note:
      "A broad clinical review showing how small studies, mixed botanicals, and preparation differences limit conclusions across herbal sleep products.",
  },
  nccihKava: {
    title: "Kava: Usefulness and Safety",
    publication: "National Center for Complementary and Integrative Health",
    year: 2026,
    url: "https://www.nccih.nih.gov/health/kava",
    note:
      "Current federal review of Pacific history, anxiety evidence, limited insomnia research, liver injury, interactions, and preparation uncertainty.",
  },
  kavaAnxietyReview2018: {
    title: "Kava for generalised anxiety disorder: a systematic review",
    publication: "Journal of Clinical Psychopharmacology",
    year: 2018,
    url: "https://pubmed.ncbi.nlm.nih.gov/30396607/",
    note:
      "A review suggesting possible short-term anxiety benefits while emphasizing limited studies and safety concerns rather than direct insomnia efficacy.",
  },
  kavaSleepTrial2004: {
    title: "Effects of kava and valerian on stress-induced insomnia",
    publication: "Phytotherapy Research",
    year: 2004,
    url: "https://pubmed.ncbi.nlm.nih.gov/14706720/",
    note:
      "A small trial in people with anxiety-related sleep disturbance using a specific extract, not proof for ordinary insomnia or every kava beverage.",
  },
  kavaInternetTrial2005: {
    title:
      "Internet-based randomized trial of kava and valerian for anxiety and insomnia",
    publication: "Medicine",
    year: 2005,
    url: "https://pubmed.ncbi.nlm.nih.gov/16010204/",
    note:
      "A 391-person trial in which kava did not outperform placebo for anxiety and valerian did not outperform placebo for insomnia.",
  },
  cdcKavaKratom2026: {
    title:
      "Increase in Poison Center Reports Linked to Kratom-Containing Kava Products",
    publication: "CDC Morbidity and Mortality Weekly Report",
    year: 2026,
    url: "https://www.cdc.gov/mmwr/volumes/75/wr/mm7512a1.htm",
    note:
      "Current U.S. poison-center surveillance separating kava from products that also contain kratom and documenting serious multi-substance outcomes.",
  },
  aasmPharmacologic2017: {
    title:
      "Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults",
    publication: "American Academy of Sleep Medicine",
    year: 2017,
    url: "https://aasm.org/wp-content/uploads/2017/07/PharmacologicTreatmentofInsomnia.pdf",
    note:
      "Evidence-graded guidance for prescription and over-the-counter insomnia drugs, including a recommendation against diphenhydramine.",
  },
  diphenhydramineTolerance2002: {
    title: "Tolerance to daytime sedative effects of H1 antihistamines",
    publication: "Journal of Clinical Psychopharmacology",
    year: 2002,
    url: "https://pubmed.ncbi.nlm.nih.gov/12352276/",
    note:
      "A small randomized crossover study finding rapid tolerance to diphenhydramine's sedative and performance effects on its tested regimen.",
  },
  diphenhydramineNextDay2010: {
    title:
      "Next-day residual sedative effect after nighttime diphenhydramine",
    publication: "Journal of Clinical Psychopharmacology",
    year: 2010,
    url: "https://pubmed.ncbi.nlm.nih.gov/21105284/",
    note:
      "A placebo-controlled PET study documenting next-day brain receptor occupancy and residual impairment after nighttime use.",
  },
  anticholinergicDementia2015: {
    title:
      "Cumulative use of strong anticholinergics and incident dementia",
    publication: "JAMA Internal Medicine",
    year: 2015,
    url: "https://pubmed.ncbi.nlm.nih.gov/25621434/",
    note:
      "A prospective cohort finding a dose-response association across strong anticholinergic drug classes, without proving that diphenhydramine causes dementia.",
  },
  anticholinergicDementia2019: {
    title: "Anticholinergic drug exposure and the risk of dementia",
    publication: "JAMA Internal Medicine",
    year: 2019,
    url: "https://pubmed.ncbi.nlm.nih.gov/31233095/",
    note:
      "A large nested case-control study finding class-specific associations and illustrating why pooled anticholinergic signals require careful interpretation.",
  },
  anticholinergicDementia2025: {
    title: "Anticholinergic burden and incident dementia",
    publication: "Age and Ageing",
    year: 2025,
    url: "https://pubmed.ncbi.nlm.nih.gov/41121438/",
    note:
      "A nationwide case-control study reporting a nonlinear dose-response association, including signals within strong antihistamines.",
  },
  blueGlassesMeta2025: {
    title:
      "Efficacy of blue-light blocking glasses on actigraphic sleep outcomes",
    publication: "Frontiers in Neurology",
    year: 2025,
    url: "https://pubmed.ncbi.nlm.nih.gov/41341515/",
    note:
      "A three-trial meta-analysis of 49 adults finding no significant objective improvement in sleep latency, duration, efficiency, or awakenings.",
  },
  blueGlassesCochrane2023: {
    title:
      "Blue-light filtering spectacle lenses for visual performance, sleep, and macular health",
    publication: "Cochrane Database of Systematic Reviews",
    year: 2023,
    url: "https://pubmed.ncbi.nlm.nih.gov/37593770/",
    note:
      "A broad review finding inconsistent sleep results and uncertain benefit from blue-light filtering spectacle lenses.",
  },
  screenRestriction2020: {
    title:
      "Restricting mobile phone use before bedtime: a randomized pilot trial",
    publication: "PLOS ONE",
    year: 2020,
    url: "https://pubmed.ncbi.nlm.nih.gov/32040492/",
    note:
      "A 38-person four-week pilot reporting improvements after stopping phone use 30 minutes before bed, with limited scale and mostly self-reported outcomes.",
  },
  tabletLight2018: {
    title:
      "Evening use of light-emitting tablets and sleep in healthy adults",
    publication: "Physiological Reports",
    year: 2018,
    url: "https://pubmed.ncbi.nlm.nih.gov/29845764/",
    note:
      "A controlled study separating evening light exposure from ordinary device use and measuring melatonin, alertness, and sleep-related outcomes.",
  },
  blueGlassUtility2025: {
    title:
      "Optimizing the potential utility of blue-blocking glasses for sleep and circadian health",
    publication: "Sleep Medicine Reviews",
    year: 2025,
    url: "https://pubmed.ncbi.nlm.nih.gov/40728371/",
    note:
      "A practical review emphasizing spectral transmission, coverage, timing, adherence, and the large differences among products sold under one label.",
  },
  uvexConsumerReports2017: {
    title: "Three blue blockers put to the test",
    publication: "Consumer Reports",
    year: 2017,
    url: "https://www.consumerreports.org/eyeglass-stores/3-blue-blockers-put-to-the-test/",
    note:
      "Independent consumer testing that found the orange Uvex Skyper filtered far more short-wavelength light than several lightly tinted alternatives.",
  },
  swanwickTransmission2026: {
    title: "Independent lens transmission reports for Sleep Swannies",
    publication: "Swanwick Sleep",
    year: 2026,
    url: "https://swanwicksleep.zendesk.com/hc/en-us/articles/360003219995-Can-I-See-Independent-Tests-Showing-What-Percentage-Of-Blue-Light-Swannies-Block",
    note:
      "A manufacturer-hosted laboratory-transmission disclosure useful for checking the product's filter, not independent proof that it improves insomnia.",
  },
  fdaZDrugs2019: {
    title: "Taking Z-drugs for insomnia? Know the risks",
    publication: "U.S. Food and Drug Administration",
    year: 2019,
    url: "https://www.fda.gov/consumers/consumer-updates/taking-z-drugs-insomnia-know-risks",
    note:
      "Official safety guidance on zolpidem, zaleplon, and eszopiclone, including complex sleep behaviors and next-day impairment.",
  },
  zaleplonLabel2019: {
    title: "Zaleplon prescribing information",
    publication: "U.S. Food and Drug Administration",
    year: 2019,
    url: "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020859s016lbl.pdf",
    note:
      "Primary regulatory source for zaleplon's short elimination half-life, sleep-onset indication, limitations, warnings, and observed outcomes.",
  },
  eszopicloneLabel2014: {
    title: "Lunesta prescribing information",
    publication: "U.S. Food and Drug Administration",
    year: 2014,
    url: "https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021476s030lbl.pdf",
    note:
      "Primary regulatory source for eszopiclone pharmacokinetics, sleep-maintenance use, next-day impairment warning, and adverse effects.",
  },
  hypnoticFdaMeta2012: {
    title:
      "Efficacy of non-benzodiazepine hypnotics in treatment of adult insomnia",
    publication: "BMJ",
    year: 2012,
    url: "https://pubmed.ncbi.nlm.nih.gov/23248080/",
    note:
      "A meta-analysis using submitted FDA data that found statistically significant but generally small average benefits and a placebo response.",
  },
  zDrugReview2012: {
    title: "Clinical pharmacology of sleep medications",
    publication: "Sleep Medicine Clinics",
    year: 2012,
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC3504423/",
    note:
      "A pharmacology review comparing half-lives, target symptoms, residual effects, and uncertain clinical significance of sleep-architecture changes.",
  },
  oxybateLabel2025: {
    title: "XYWAV and XYREM prescribing information and REMS",
    publication: "U.S. Food and Drug Administration",
    year: 2025,
    url: "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021196Orig1s047%2C212690Orig1s017lbl.pdf",
    note:
      "Current regulatory source for approved uses, restricted distribution, CNS and respiratory depression, abuse, interactions, and other serious risks.",
  },
  oxybateNarcolepsyMeta2019: {
    title:
      "Gamma-hydroxybutyrate for narcolepsy in adults: a systematic review and meta-analysis",
    publication: "Sleep Medicine",
    year: 2019,
    url: "https://pubmed.ncbi.nlm.nih.gov/31671326/",
    note:
      "A 15-trial synthesis finding benefits for narcolepsy symptoms and sleep measures alongside dose-related tolerability problems.",
  },
  oxybatePhysiological2012: {
    title:
      "Differential effects of sodium oxybate and baclofen on EEG, sleep, performance, and memory",
    publication: "Sleep",
    year: 2012,
    url: "https://pubmed.ncbi.nlm.nih.gov/22851803/",
    note:
      "A controlled experiment showing that drug-induced slow EEG waves were not necessarily functionally equivalent to ordinary physiological slow-wave sleep.",
  },
  oxybateMdd2025: {
    title:
      "Gamma-hydroxybutyrate to promote slow-wave sleep in major depressive disorder",
    publication: "Journal of Psychopharmacology",
    year: 2025,
    url: "https://pubmed.ncbi.nlm.nih.gov/40229541/",
    note:
      "A small randomized crossover trial in a specific clinical population, useful as experimental evidence rather than support for self-treatment.",
  },
  oxybateHealthy2026: {
    title:
      "Sodium oxybate alters sleep architecture and memory-related responses",
    publication: "Journal of Sleep Research",
    year: 2026,
    url: "https://pubmed.ncbi.nlm.nih.gov/42267755/",
    note:
      "A 19-person healthy-volunteer crossover study showing altered architecture and memory-related effects, not a general insomnia benefit.",
  },
  erowidGhbOverdose: {
    title: "GHB experience report: An overdose",
    publication: "Erowid Experience Vaults",
    year: 2000,
    url: "https://www.erowid.org/experiences/exp.php?ID=45",
    note:
      "An unverified first-person report included only to document the kinds of dosing uncertainty and acute harm described outside clinical settings.",
  },
  erowidGhbWithdrawal: {
    title: "GHB experience report: Dependence and withdrawal insomnia",
    publication: "Erowid Experience Vaults",
    year: 2003,
    url: "https://www.erowid.org/experiences/exp.php?ID=13866",
    note:
      "An unverified account describing escalating use and withdrawal insomnia; useful for question discovery, not frequency or causality estimates.",
  },
  erowidGhbVariable: {
    title: "GHB experience report: Short duration and variable sleep",
    publication: "Erowid Experience Vaults",
    year: 2004,
    url: "https://www.erowid.org/experiences/exp.php?ID=20916",
    note:
      "An unverified report illustrating why subjective claims of restorative sleep cannot substitute for controlled outcomes or safe pharmaceutical use.",
  },
  fdaKratom2026: {
    title: "FDA and Kratom",
    publication: "U.S. Food and Drug Administration",
    year: 2026,
    url: "https://www.fda.gov/news-events/public-health-focus/fda-and-kratom",
    note:
      "Current federal summary of unapproved uses, opioid-receptor activity, dependence, adverse events, contamination, and regulatory concerns.",
  },
  cdcKratom2026: {
    title:
      "Increases in Kratom-Related Reports to Poison Centers, 2015–2025",
    publication: "CDC Morbidity and Mortality Weekly Report",
    year: 2026,
    url: "https://www.cdc.gov/mmwr/volumes/75/wr/mm7511a1.htm",
    note:
      "Current national surveillance documenting rising reports, hospitalizations, serious outcomes, high-potency products, and multi-substance risk.",
  },
  kratomWithdrawal2019: {
    title: "Kratom withdrawal: a systematic review with case series",
    publication: "Journal of Psychoactive Drugs",
    year: 2019,
    url: "https://pubmed.ncbi.nlm.nih.gov/30614408/",
    note:
      "A systematic clinical review describing tolerance, dependence, withdrawal, and the limits of the available evidence.",
  },
  kratomDependence2024: {
    title:
      "Kratom use disorder and physical dependence: amount versus frequency",
    publication: "Drug and Alcohol Dependence",
    year: 2024,
    url: "https://pubmed.ncbi.nlm.nih.gov/38788532/",
    note:
      "A study finding that dependence and use-disorder indicators become more likely as consumption frequency increases.",
  },
  kratomForum2026: {
    title: "Community discussion: poor sleep after later-day kratom use",
    publication: "Reddit r/kratom",
    year: 2026,
    url: "https://www.reddit.com/r/kratom/comments/1s1dee7/poor_sleep_caused_by_kratom_consumed_later_in_the/",
    note:
      "A recent self-report thread showing conflicting experiences of energy, sleep disruption, and a later crash; anecdotal and selection-biased.",
  },
  toDoList2018: {
    title:
      "The effects of bedtime writing on difficulty falling asleep",
    publication: "Journal of Experimental Psychology: General",
    year: 2018,
    url: "https://pubmed.ncbi.nlm.nih.gov/29058942/",
    note:
      "A one-night laboratory study of 57 healthy young adults finding faster sleep onset after a specific five-minute future to-do list.",
  },
  constructiveWorry2006: {
    title:
      "Constructive worry as an intervention for insomnia and bedtime cognitive arousal",
    publication: "Behaviour Research and Therapy",
    year: 2006,
    url: "https://pubmed.ncbi.nlm.nih.gov/16390282/",
    note:
      "A small study asking students with insomnia to write worries and next steps before bed, with reduced pre-sleep cognitive arousal.",
  },
  clockMonitoring2006: {
    title: "The effect of clock monitoring on insomnia",
    publication: "Behaviour Research and Therapy",
    year: 2006,
    url: "https://pubmed.ncbi.nlm.nih.gov/16793001/",
    note:
      "Experimental evidence that monitoring time can increase worry and perceived sleep-onset difficulty.",
  },
  cognitiveReview2024: {
    title: "Cognitive factors in insomnia: a systematic review",
    publication: "Sleep Medicine Reviews",
    year: 2024,
    url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC10909484/",
    note:
      "A broad synthesis of worry, rumination, attention, beliefs, and sleep effort that supports a multi-mechanism view of the racing-mind problem.",
  },
  mindfulnessMeta2022: {
    title:
      "Mindfulness meditation for insomnia: an updated systematic review and meta-analysis",
    publication: "Sleep Medicine Reviews",
    year: 2022,
    url: "https://pubmed.ncbi.nlm.nih.gov/36332952/",
    note:
      "An updated synthesis finding mixed effects and no basis for treating mindfulness alone as a universal substitute for CBT-I.",
  },
} as const;

export const SLEEP_HEALTH_ARTICLES = [
  {
    slug: "best-magnesium-for-sleep",
    title: "Best Magnesium for Sleep? What the Evidence Actually Shows",
    dek:
      "Magnesium glycinate is popular, but no head-to-head sleep trial proves one form is best. The useful choice depends on deficiency, elemental magnesium, tolerability, and product quality.",
    seoDescription:
      "Compare magnesium glycinate, citrate, oxide, and L-threonate for sleep. See what trials show, how labels work, and why no form is proven best.",
    focusPhrase: "best magnesium for sleep",
    keywords: [
      "magnesium glycinate for sleep",
      "magnesium citrate vs glycinate sleep",
      "magnesium L-threonate sleep",
      "which magnesium helps sleep",
      "magnesium sleep evidence",
    ],
    tags: ["sleep", "supplements", "wellness-claims"],
    evidenceLabel: "Small benefits are possible; no form is proven best",
    publishedAt: "2026-08-28",
    updatedAt: "2026-08-28",
    sourceIds: [
      "magnesiumOds",
      "magnesiumMeta2021",
      "magnesiumReview2022",
      "magnesiumThreonate2024",
      "magnesiumBisglycinate2025",
      "fdaSupplements",
      "uspVerification",
      "cbtiGuideline2021",
    ],
    relatedSlugs: [
      "l-theanine-valerian-california-poppy-for-sleep",
      "how-to-quiet-a-racing-mind-at-night",
      "morning-sunlight-and-sleep",
    ],
    body: [
      callout(
        "The short answer",
        "Magnesium may modestly improve subjective sleep in some people, especially when intake is low, but the evidence is too small and inconsistent to name a universally best form. Glycinate is often chosen because it may be easier on the gut than oxide. Citrate is relatively well absorbed but can loosen stools. L-threonate has a recent positive trial but no proof of superiority. The strongest buying criteria are the elemental amount, a reason to supplement, tolerability, interactions, and independent quality verification.",
      ),
      heading("Why the internet always says glycinate"),
      paragraph(
        "Search results tend to collapse three different questions into one: which magnesium salt is absorbed, which is tolerated, and which improves sleep. The ",
        link("NIH magnesium fact sheet", SLEEP_HEALTH_SOURCES.magnesiumOds.url),
        " says forms that dissolve well, including citrate, chloride, lactate, and aspartate, tend to be more bioavailable than oxide and sulfate. That is not a sleep ranking. Glycinate is widely marketed as calming because glycine is an inhibitory amino acid and because the form is often tolerated well, but direct sleep trials comparing glycinate against citrate, oxide, or threonate are missing.",
      ),
      paragraph(
        "A product label also lists elemental magnesium, not the full weight of the magnesium compound. Two bottles can advertise different compound sizes while delivering similar elemental amounts. Comparing the front label alone therefore produces false precision.",
      ),
      table(
        "How common magnesium forms differ",
        ["Form", "What is reasonably known", "What sleep evidence does not establish"],
        [
          item("Glycinate or bisglycinate"),
          item("Commonly well tolerated; one 2025 trial found a small subjective insomnia-score benefit"),
          item("No head-to-head evidence that it is the best form for sleep or that glycine explains the result"),
        ],
        [
          item("Citrate"),
          item("Relatively soluble and absorbed; also used because it can draw water into the bowel"),
          item("No evidence that a laxative effect or higher absorption automatically produces better sleep"),
        ],
        [
          item("Oxide"),
          item("Lower fractional absorption and more gastrointestinal effects for some people; inexpensive"),
          item("Lower absorption does not mean zero absorption, and sleep trials do not provide a clean form ranking"),
        ],
        [
          item("L-threonate"),
          item("A 2024 randomized trial reported subjective sleep and daytime changes"),
          item("No direct comparison with glycinate or citrate, and industry context plus subjective outcomes limit certainty"),
        ],
      ),
      heading("What the sleep trials show"),
      paragraph(
        "The ",
        link("2021 meta-analysis", SLEEP_HEALTH_SOURCES.magnesiumMeta2021.url),
        " found only three eligible randomized trials with 151 older adults. Pooled sleep-onset latency looked about 17 minutes shorter, but the reviewers rated the evidence low to very low because the studies were small and at risk of bias. A ",
        link("2022 systematic review", SLEEP_HEALTH_SOURCES.magnesiumReview2022.url),
        " found that observational magnesium status often tracked with sleep, while randomized results were contradictory.",
      ),
      paragraph(
        "More recent form-specific trials add information without resolving the ranking. A ",
        link("2024 L-threonate trial", SLEEP_HEALTH_SOURCES.magnesiumThreonate2024.url),
        " reported better self-rated sleep and daytime functioning in adults with sleep complaints. A ",
        link("2025 bisglycinate trial", SLEEP_HEALTH_SOURCES.magnesiumBisglycinate2025.url),
        " found a small four-week change in insomnia scores, with the between-group result close to the conventional significance threshold. Neither was a direct comparison among forms, and neither turns magnesium into a treatment for chronic insomnia.",
      ),
      heading("A better way to decide"),
      ordered(
        item(strong("Start with the reason. "), "Low intake, a documented deficiency, a medication effect, and a vague hope for deeper sleep are different situations."),
        item(strong("Read elemental magnesium. "), "Use the Supplement Facts panel rather than comparing the compound weight or a proprietary blend."),
        item(strong("Choose for tolerance and the actual job. "), "Citrate may be useful when constipation is also relevant; a gentler form may matter when loose stools are the problem."),
        item(strong("Check the whole formula. "), "Many sleep blends add melatonin, herbs, or sedating ingredients, making it impossible to know what produced an effect."),
        item(strong("Prefer verified quality. "), "USP or NSF product certification can support identity and contaminant control. It does not prove that the supplement improves sleep."),
      ),
      heading("Safety is not a footnote"),
      paragraph(
        "The NIH sets an adult upper limit of 350 milligrams per day for magnesium from supplements and medications, excluding food, unless a clinician directs otherwise. Too much supplemental magnesium commonly causes diarrhea, nausea, and cramping. Very high exposure can cause dangerous cardiovascular effects, especially when kidney function is impaired. Magnesium also interacts with some antibiotics, osteoporosis drugs, and other medicines.",
      ),
      paragraph(
        "Food sources such as legumes, nuts, seeds, whole grains, and leafy vegetables supply magnesium with other nutrients and do not count toward the supplemental upper limit. If persistent insomnia is the problem, the ",
        link(
          "AASM behavioral guideline",
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC7853203/",
        ),
        " gives multicomponent cognitive behavioral therapy for insomnia a far stronger evidence base than magnesium. A supplement can be a bounded experiment. It should not become an explanation for every bad night.",
      ),
    ],
  },
  {
    slug: "l-theanine-valerian-california-poppy-for-sleep",
    title: "L-Theanine, Valerian & California Poppy for Sleep",
    dek:
      "These three sleep supplements come from different traditions and have very different evidence. L-theanine is promising but uncertain, valerian is inconsistent, and California poppy still rests heavily on traditional use.",
    seoDescription:
      "Compare L-theanine, valerian root, and California poppy for sleep, including clinical evidence, traditional use, preparations, quality, and risks.",
    focusPhrase: "L-theanine valerian California poppy for sleep",
    keywords: [
      "L-theanine for sleep",
      "valerian root for sleep",
      "California poppy for sleep",
      "herbs for insomnia",
      "natural sleep aids evidence",
    ],
    tags: ["sleep", "supplements", "wellness-claims"],
    evidenceLabel: "Promising signals, inconsistent trials, and traditional use",
    publishedAt: "2026-08-28",
    updatedAt: "2026-08-28",
    sourceIds: [
      "lTheanineMeta2025",
      "lTheanineReview2026",
      "valerianUmbrella2024",
      "nccihValerian",
      "californiaPoppyEma",
      "californiaValerianTrial2026",
      "plantExtractSleepReview2020",
      "fdaSupplements",
      "uspVerification",
    ],
    relatedSlugs: [
      "best-magnesium-for-sleep",
      "kava-for-sleep",
      "benadryl-diphenhydramine-for-sleep",
    ],
    body: [
      callout(
        "The short answer",
        "L-theanine has the most promising recent synthesis of the three, but its benefits are modest and often subjective. Valerian has centuries of use and some positive trials, yet a 2024 umbrella review found no demonstrated efficacy for insomnia. California poppy is recognized by European regulators for traditional use, not proven clinical benefit. No strain, extract, or combination is established as best. Botanical identity, plant part, preparation, interactions, and independent testing matter more than a romantic label.",
      ),
      heading("Three substances, three different traditions"),
      paragraph(
        "L-theanine is an amino acid associated with tea, especially ",
        "Camellia sinensis",
        ". Tea culture has a long history, but a bedtime cup of green tea is not equivalent to a purified L-theanine trial because ordinary tea can contain caffeine and many other compounds. Theanine is better understood as a possible relaxation aid than a direct sedative.",
      ),
      paragraph(
        "Valerian usually means the root or rhizome of ",
        "Valeriana officinalis",
        ". Greek and Roman medical writers described it, and European herbal medicine has long used it for nervousness and sleep. California poppy means ",
        "Eschscholzia californica",
        ", usually the dried above-ground parts. It is not the opium poppy, ",
        "Papaver somniferum",
        ", and should not be described as a natural opioid.",
      ),
      table(
        "What the evidence supports in 2026",
        ["Ingredient", "Best direct evidence", "Current boundary"],
        [
          item("L-theanine"),
          item("Recent systematic reviews find modest improvements in some subjective sleep measures"),
          item("Few pure-ingredient insomnia trials, mixed populations, uncertain objective effects, and no proven optimal preparation"),
        ],
        [
          item("Valerian root"),
          item("Some individual trials and subjective sleep-quality signals"),
          item("Umbrella review found no demonstrated efficacy for insomnia; extracts vary substantially"),
        ],
        [
          item("California poppy herb"),
          item("Traditional-use recognition plus one recent positive combination trial"),
          item("The combination cannot isolate California poppy, and traditional registration is not clinical proof"),
        ],
      ),
      heading("L-theanine: promising, not settled"),
      paragraph(
        "A ",
        link("2025 systematic review and meta-analysis", SLEEP_HEALTH_SOURCES.lTheanineMeta2025.url),
        " included 19 articles and 897 participants. It found modest changes in several self-reported sleep outcomes, while noting that many studies used combinations or populations without diagnosed insomnia. A ",
        link("2026 standalone-intervention review", SLEEP_HEALTH_SOURCES.lTheanineReview2026.url),
        " was more optimistic, but the review team included research affiliations with British American Tobacco. That does not erase the data. It increases the importance of independent replication and objective outcomes.",
      ),
      paragraph(
        "There is no credible evidence that a particular tea cultivar, fermentation style, or branded source is the best sleep aid. If the goal is to test L-theanine, a single-ingredient product makes the experiment easier to interpret than a multi-ingredient powder. A caffeinated tea can work against the bedtime goal even if it contains theanine.",
      ),
      heading("Valerian: preparation matters, but does not rescue weak evidence"),
      paragraph(
        "The ",
        link("2024 umbrella review", SLEEP_HEALTH_SOURCES.valerianUmbrella2024.url),
        " examined eight systematic reviews. It found no evidence that valerian effectively treats insomnia, although subjective sleep quality sometimes improved. Trials used different species, roots, extraction solvents, chemical markers, schedules, populations, and outcome measures. That heterogeneity is a real limitation, not permission to declare that one favored extract must work.",
      ),
      paragraph(
        "A consumer should at least look for the full botanical name, plant part, extract ratio or preparation, and an independently verified product. Whole root, aqueous extracts, and standardized extracts are not interchangeable. The ",
        link("NCCIH safety review", SLEEP_HEALTH_SOURCES.nccihValerian.url),
        " says short-term use appears generally tolerated but long-term safety is unknown. Headache, stomach upset, mental dullness, excitability, and vivid dreams can occur, and combining valerian with alcohol or sedatives is a poor experiment.",
      ),
      heading("California poppy: a new trial, still a combination"),
      paragraph(
        "The ",
        link("European Medicines Agency", SLEEP_HEALTH_SOURCES.californiaPoppyEma.url),
        " permits a traditional-use conclusion for California poppy aerial parts used to aid sleep. In regulatory language, that means long-standing use makes the indication plausible even though clinical trials remain insufficient.",
      ),
      paragraph(
        "A ",
        link("2026 randomized trial", SLEEP_HEALTH_SOURCES.californiaValerianTrial2026.url),
        " found a larger insomnia-score improvement with a fixed California-poppy-and-valerian extract than placebo in adults with insomnia associated with anxiety. It is useful new evidence. It cannot tell us whether California poppy worked, valerian worked, their combination mattered, or the result generalizes to tea, tincture, whole herb, another extract, or ordinary chronic insomnia.",
      ),
      heading("Related herbs do not inherit each other's evidence"),
      paragraph(
        "Chamomile, passionflower, lemon balm, lavender, and hops appear in traditional sleep formulas. Their histories and chemistry differ, and evidence for one does not validate a blend containing five. Combination products create a particular interpretive problem: even when a trial is positive, the active contributor and interaction remain uncertain. They also make adverse reactions and drug interactions harder to trace.",
      ),
      unordered(
        item(strong("For a clean experiment: "), "change one ingredient at a time and keep the rest of the evening routine stable."),
        item(strong("For botanical quality: "), "look for species, plant part, preparation, lot information, and independent contaminant and identity testing."),
        item(strong("For safety: "), "check sedatives, alcohol, pregnancy, liver disease, and other medicines with a pharmacist or clinician."),
        item(strong("For persistent insomnia: "), "treat herbs as optional adjuncts, not substitutes for evaluation or CBT-I."),
      ),
      paragraph(
        "The most defensible ranking is not “strongest herb.” It is an evidence ladder. L-theanine has a growing but still uncertain modern evidence base. Valerian has a large historical footprint and inconsistent clinical results. California poppy has traditional-use recognition and a promising new combination trial. All three need better independent, preparation-specific, objective sleep studies.",
      ),
    ],
  },
  {
    slug: "kava-for-sleep",
    title: "Kava for Sleep: Tradition, Evidence, and Liver Risk",
    dek:
      "Kava has a deep Pacific cultural history and some anxiety evidence, but little direct insomnia evidence. “Noble” cultivars and water preparation do not eliminate the documented safety uncertainty.",
    seoDescription:
      "Does kava help sleep? Review Pacific traditional use, anxiety and insomnia trials, noble cultivars, preparation differences, interactions, and liver risk.",
    focusPhrase: "kava for sleep",
    keywords: [
      "does kava help sleep",
      "kava insomnia",
      "kava sleep quality",
      "noble kava safety",
      "kava liver risk",
    ],
    tags: ["sleep", "supplements", "wellness-claims"],
    evidenceLabel: "Little insomnia evidence and meaningful safety uncertainty",
    publishedAt: "2026-08-28",
    updatedAt: "2026-08-28",
    sourceIds: [
      "nccihKava",
      "kavaAnxietyReview2018",
      "kavaSleepTrial2004",
      "kavaInternetTrial2005",
      "cdcKavaKratom2026",
      "fdaSupplements",
      "cbtiGuideline2021",
    ],
    relatedSlugs: [
      "l-theanine-valerian-california-poppy-for-sleep",
      "ghb-sodium-oxybate-and-sleep",
      "kratom-after-no-sleep",
    ],
    body: [
      callout(
        "The short answer",
        "Kava may reduce anxiety for some people, and less anxiety can feel sleep-promoting, but direct evidence for insomnia is sparse. Rare severe liver injury has been reported with multiple product types, including some water-prepared beverages. Choosing a so-called noble cultivar, root-only material, or traditional water preparation may improve traceability, but none is a safety guarantee. Kava should not be combined with alcohol, benzodiazepines, sleep medicines, or other sedatives.",
      ),
      heading("What kava is, and why context matters"),
      paragraph(
        "Kava is ",
        "Piper methysticum",
        ", a plant in the pepper family. Pacific peoples have prepared kava beverages for ceremonial, social, and medicinal use for thousands of years. Removing that context and selling a concentrated capsule as an ancient sleep hack changes the preparation, setting, frequency, and quality controls at once.",
      ),
      paragraph(
        "The ",
        link("NCCIH kava review", SLEEP_HEALTH_SOURCES.nccihKava.url),
        " distinguishes the relatively larger anxiety literature from the much smaller sleep literature. A substance can ease anxiety without treating chronic insomnia, and feeling sedated is not the same as restoring normal sleep architecture or next-day function.",
      ),
      heading("What the trials actually measured"),
      table(
        "Direct and indirect kava evidence",
        ["Evidence", "Finding", "Why it does not answer everything"],
        [
          item("Anxiety systematic reviews"),
          item("Some short-term anxiety reduction in selected trials"),
          item("Anxiety outcomes are adjacent to sleep, not direct insomnia efficacy"),
        ],
        [
          item("Small stress-related insomnia trial"),
          item("A specific kava extract was associated with sleep changes in an anxious population"),
          item("Small sample, particular extract, and anxiety-linked sleep disturbance limit generalization"),
        ],
        [
          item("391-person internet trial"),
          item("Kava did not beat placebo for anxiety; valerian did not beat placebo for insomnia"),
          item("Shows that expectancy and trial design matter even for familiar herbal products"),
        ],
      ),
      paragraph(
        "A ",
        link("2018 anxiety review", SLEEP_HEALTH_SOURCES.kavaAnxietyReview2018.url),
        " found possible short-term benefit but did not establish kava as an insomnia treatment. A ",
        link("small 2004 sleep study", SLEEP_HEALTH_SOURCES.kavaSleepTrial2004.url),
        " involved anxiety-related sleep disturbance and a defined extract. By contrast, a ",
        link("larger internet-based trial", SLEEP_HEALTH_SOURCES.kavaInternetTrial2005.url),
        " found no advantage over placebo for its primary kava anxiety comparison.",
      ),
      heading("Noble cultivars and traditional preparation"),
      paragraph(
        "Kava communities and vendors distinguish noble cultivars from other varieties, emphasize peeled roots and rhizomes rather than aerial parts, and often prefer a water-based beverage over solvent extracts. Those distinctions are culturally and chemically meaningful. They may reduce some avoidable quality risks. Current evidence does not show that they eliminate liver injury, interactions, contamination, or individual susceptibility.",
      ),
      paragraph(
        "The NCCIH review notes that serious liver cases were first linked to alcohol- or acetone-extracted products, but cases have also involved water-prepared beverages. Proposed explanations include cultivar, plant part, adulteration, co-use with alcohol, prolonged exposure, and genetic susceptibility. A product claiming “traditional” can still have uncertain identity or concentration.",
      ),
      heading("The current U.S. market has an added confusion"),
      paragraph(
        "Some products marketed around kava bars or relaxation now include kratom or concentrated kratom alkaloids. A ",
        link("2026 CDC poison-center report", SLEEP_HEALTH_SOURCES.cdcKavaKratom2026.url),
        " found that kratom became a common co-exposure in kava-related reports. Kava and kratom are different plants with different pharmacology and risks. A label that blurs them is a reason to walk away, not an enhanced formula.",
      ),
      heading("If someone is considering kava"),
      unordered(
        item("Do not combine it with alcohol, benzodiazepines, opioids, antihistamine sleep aids, Z-drugs, or other sedatives."),
        item("Avoid products that hide quantities or mix kava with kratom, 7-hydroxymitragynine, or an unnamed proprietary relaxation blend."),
        item("Treat cultivar, plant part, extraction, and independent identity testing as traceability information, not efficacy or safety proof."),
        item("Discuss liver disease, pregnancy, breastfeeding, and medication interactions with a qualified clinician or pharmacist."),
        item("Stop treating an herbal ritual as harmless if jaundice, dark urine, unusual fatigue, abdominal symptoms, or other concerning effects appear."),
      ),
      paragraph(
        "Kava's traditional importance deserves respect, and its anxiety evidence deserves accurate description. Neither justifies turning it into a routine sleep recommendation. For ongoing insomnia, multicomponent CBT-I has a substantially stronger benefit-risk case. Kava remains a culturally significant plant with possible short-term anxiety effects, weak direct sleep evidence, and a safety profile that requires more caution than the word natural suggests.",
      ),
      paragraph(
        "A calm ritual around a kava beverage may also include conversation, reduced screen use, a familiar setting, and time separated from work. Those contextual effects can be genuinely relaxing without proving that kavalactones improve insomnia. Preserving that distinction respects both lived experience and the scientific question.",
      ),
    ],
  },
  {
    slug: "benadryl-diphenhydramine-for-sleep",
    title: "Benadryl for Sleep: Grogginess, Tolerance & Dementia Risk",
    dek:
      "Diphenhydramine can make people drowsy, but sleep benefits are small, tolerance develops quickly, and next-day impairment is real. Dementia studies show an association with anticholinergic burden, not simple proof of causation.",
    seoDescription:
      "Is Benadryl safe for sleep? Review diphenhydramine tolerance, next-day grogginess, anticholinergic effects, dementia studies, and insomnia guidance.",
    focusPhrase: "Benadryl for sleep dementia risk",
    keywords: [
      "diphenhydramine for sleep",
      "Benadryl sleep aid",
      "Benadryl dementia risk",
      "antihistamine sleep grogginess",
      "PM medicine sleep",
    ],
    tags: ["sleep", "medications", "wellness-claims"],
    evidenceLabel: "Weak sleep benefit, rapid tolerance, and avoidable risk",
    publishedAt: "2026-08-28",
    updatedAt: "2026-08-28",
    sourceIds: [
      "aasmPharmacologic2017",
      "diphenhydramineTolerance2002",
      "diphenhydramineNextDay2010",
      "anticholinergicDementia2015",
      "anticholinergicDementia2019",
      "anticholinergicDementia2025",
      "cbtiGuideline2021",
    ],
    relatedSlugs: [
      "z-drugs-zaleplon-zolpidem-eszopiclone",
      "how-to-quiet-a-racing-mind-at-night",
      "is-eight-hours-of-sleep-necessary",
    ],
    body: [
      callout(
        "The short answer",
        "Diphenhydramine, sold as Benadryl and in many “PM” products, is a poor routine sleep aid. It can cause drowsiness, but controlled insomnia benefits are small and below clinically meaningful thresholds in the AASM review. Tolerance to sedation can develop within days, while dry mouth, constipation, urinary retention, confusion, falls, and next-day impairment remain concerns. Long-term strong anticholinergic exposure is associated with dementia in observational studies, but those studies do not prove that occasional Benadryl causes Alzheimer's disease.",
      ),
      heading("Drowsiness is not the same as useful sleep"),
      paragraph(
        "Diphenhydramine is a first-generation antihistamine that crosses into the brain and also has strong anticholinergic effects. The sedating side effect made it a common ingredient in over-the-counter nighttime products. A drug can make eyes heavy without materially improving total sleep, awakenings, restorative function, or the underlying cause of insomnia.",
      ),
      paragraph(
        "The ",
        link("AASM pharmacologic guideline", SLEEP_HEALTH_SOURCES.aasmPharmacologic2017.url),
        " reviewed controlled trials and suggested that clinicians not use diphenhydramine for sleep-onset or sleep-maintenance insomnia. Average improvements in reported latency and total sleep time fell below the guideline's thresholds for clinical significance.",
      ),
      heading("Why it often stops working"),
      paragraph(
        "In a ",
        link("small randomized crossover study", SLEEP_HEALTH_SOURCES.diphenhydramineTolerance2002.url),
        ", 15 healthy men received repeated daytime diphenhydramine or placebo. Objective and subjective sedation was clear initially, then tolerance was complete by the end of three days on that regimen. A daytime trial is not a nightly insomnia trial, but it demonstrates how rapidly the desired sedating effect can fade.",
      ),
      paragraph(
        "That creates a bad feedback loop. Someone experiences a strong first night, repeats the product, gets less effect, and may escalate or add other sedatives. The fading drowsiness does not mean the anticholinergic burden or interaction risk disappeared.",
      ),
      heading("The morning-after problem"),
      paragraph(
        "Diphenhydramine has a long enough and variable enough effect to reach into the next day. A ",
        link("placebo-controlled PET study", SLEEP_HEALTH_SOURCES.diphenhydramineNextDay2010.url),
        " found residual brain H1-receptor occupancy and impairment the next morning. People describe this as a hangover, fog, heavy limbs, slowed reaction time, or feeling that sleep did not restore them.",
      ),
      table(
        "What a routine diphenhydramine habit trades",
        ["What feels helpful", "What may be happening", "Why the trade matters"],
        [
          item("Rapid drowsiness"),
          item("Central antihistamine and anticholinergic sedation"),
          item("Sedation can fade quickly and does not establish better sleep quality"),
        ],
        [
          item("Over-the-counter access"),
          item("Self-treatment without review of interactions or sleep disorder"),
          item("Easy access does not mean low risk, especially in older adults"),
        ],
        [
          item("Long night of unconsciousness"),
          item("Residual drug effect may continue after waking"),
          item("Driving, falls, memory, and work performance can be affected"),
        ],
      ),
      heading("Does Benadryl cause dementia?"),
      paragraph(
        "A ",
        link("2015 prospective cohort", SLEEP_HEALTH_SOURCES.anticholinergicDementia2015.url),
        " found a dose-response association between cumulative strong anticholinergic use and later dementia in adults 65 and older. First-generation antihistamines were among the common classes, but the study pooled multiple anticholinergic medicines and was observational. It cannot prove that diphenhydramine caused an individual case or convert the association into a precise safe number of nights.",
      ),
      paragraph(
        "A ",
        link("2019 case-control study", SLEEP_HEALTH_SOURCES.anticholinergicDementia2019.url),
        " found stronger associations for several other drug classes, illustrating that the signal is not identical across every anticholinergic. A ",
        link("2025 nationwide study", SLEEP_HEALTH_SOURCES.anticholinergicDementia2025.url),
        " again reported a nonlinear association and included a strong-antihistamine signal. Reverse causation, underlying illness, prescribing patterns, and unmeasured confounding remain possible. The honest wording is associated with increased risk, not proven to cause Alzheimer's disease.",
      ),
      heading("Who should be especially cautious"),
      unordered(
        item("Older adults, because confusion, falls, constipation, urinary retention, and cumulative anticholinergic burden become more consequential."),
        item("People with glaucoma, urinary retention, prostate symptoms, cognitive impairment, or medicines with anticholinergic or sedating effects."),
        item("Anyone mixing alcohol, opioids, cannabis, benzodiazepines, Z-drugs, kava, or other nighttime products."),
        item("People who must drive, supervise others, or perform safety-sensitive work the next morning."),
      ),
      paragraph(
        "An allergy problem and an insomnia problem also deserve different decisions. A clinician may have a reason to use an antihistamine for an allergic condition. That does not make it a good standing solution for chronic sleep difficulty.",
      ),
      heading("What to do instead"),
      paragraph(
        "For a recurring pattern, identify whether the problem is sleep onset, awakenings, early waking, circadian timing, breathing, restless legs, pain, substances, or a racing mind. The ",
        link("AASM behavioral guideline", "https://pmc.ncbi.nlm.nih.gov/articles/PMC7853203/"),
        " gives multicomponent CBT-I a strong recommendation. If diphenhydramine has become nightly, especially alongside other medicines, bring the full product list to a pharmacist or clinician rather than abruptly improvising a replacement stack.",
      ),
    ],
  },
  {
    slug: "screens-blue-light-glasses-and-sleep",
    title: "Screens, Blue-Light Glasses & Sleep: What Actually Helps",
    dek:
      "Evening screens combine light, arousal, and stolen time. Blue-blocking glasses filter very differently, and the latest objective meta-analysis found no significant sleep benefit. A screen-free wind-down remains a reasonable low-cost experiment.",
    seoDescription:
      "Do screens or blue-light glasses affect sleep? Review the evidence, try a 30-minute wind-down, and compare budget Uvex with premium amber options.",
    focusPhrase: "blue light glasses for sleep",
    keywords: [
      "screen time before bed",
      "30 minutes no screens before bed",
      "best blue light blocking glasses sleep",
      "Uvex Skyper blue light",
      "Swanwick sleep glasses",
    ],
    tags: ["sleep", "circadian", "environment", "wellness-claims"],
    evidenceLabel: "Light matters; glasses trials remain small and inconsistent",
    publishedAt: "2026-08-28",
    updatedAt: "2026-08-28",
    sourceIds: [
      "blueGlassesMeta2025",
      "blueGlassesCochrane2023",
      "screenRestriction2020",
      "tabletLight2018",
      "blueGlassUtility2025",
      "uvexConsumerReports2017",
      "swanwickTransmission2026",
      "lightTimingReview2019",
    ],
    relatedSlugs: [
      "morning-sunlight-and-sleep",
      "how-to-quiet-a-racing-mind-at-night",
      "why-you-sleep-badly-in-hotels",
    ],
    body: [
      callout(
        "The short answer",
        "Screens can delay sleep through at least three routes: evening light at the eyes, mentally activating content, and simply using time that would otherwise be quiet or asleep. Blue-blocking glasses can reduce short-wavelength light, but the latest objective meta-analysis found no significant improvement in sleep latency, duration, efficiency, or awakenings. A 30-minute screen-free wind-down is a reasonable experiment because it changes all three routes at once. If glasses are needed, choose a measured amber or orange filter, not a nearly clear “computer” lens.",
      ),
      heading("The screen is not one exposure"),
      paragraph(
        "“Blue light from phones ruins sleep” is too simple. Circadian response depends on spectrum, brightness at the eye, duration, timing, previous daytime light, pupil size, and individual sensitivity. A bright tablet near the face in a dark room is different from a dim warm display across a room. The content also matters: work messages, arguments, games, news, and endless short videos can maintain alertness even after the pixels are warm.",
      ),
      paragraph(
        "Controlled ",
        link("tablet-light research", SLEEP_HEALTH_SOURCES.tabletLight2018.url),
        " supports a biological effect of evening light exposure, while broader light reviews show that morning and evening timing push the circadian system in different directions. None establishes one universal device curfew for every sleeper.",
      ),
      heading("What a 30-minute screen break can and cannot prove"),
      paragraph(
        "A ",
        link("four-week randomized pilot", SLEEP_HEALTH_SOURCES.screenRestriction2020.url),
        " assigned 38 people who used phones at bedtime to stop mobile-phone use 30 minutes before bed or continue as usual. The restriction group reported faster sleep onset, longer sleep, better quality, and lower pre-sleep arousal. It was small, relied heavily on self-report, and changed behavior rather than isolating blue wavelengths.",
      ),
      paragraph(
        "That is exactly why the practice is useful. A half-hour without screens simultaneously lowers close-range light, removes stimulating feeds, creates a transition ritual, and protects time for hygiene, reading, stretching, writing, or quiet conversation. Thirty minutes is a testable starting point, not a biological threshold. Someone with a delayed circadian schedule or severe insomnia may need a broader plan.",
      ),
      heading("Do blue-light glasses improve sleep?"),
      paragraph(
        "The ",
        link("2023 Cochrane review", SLEEP_HEALTH_SOURCES.blueGlassesCochrane2023.url),
        " found inconsistent sleep results across six small randomized studies. The ",
        link("2025 objective meta-analysis", SLEEP_HEALTH_SOURCES.blueGlassesMeta2025.url),
        " pooled three crossover trials with 49 adults and found no significant effects on actigraphic sleep onset, total sleep, efficiency, or wake after sleep onset. Wide confidence intervals mean a useful effect in some contexts remains possible; they do not justify guaranteed-sleep marketing.",
      ),
      heading("How to buy a real evening filter"),
      table(
        "A practical budget-to-premium shortlist",
        ["Option", "Why it is on the list", "Trade-off and evidence boundary"],
        [
          item("Budget: Honeywell Uvex Skyper SCT-Orange"),
          item("Deep orange wraparound safety lens; independent consumer testing found strong short-wavelength filtering"),
          item("Industrial appearance and fit; product filtering is credible, but sleep improvement is not guaranteed"),
        ],
        [
          item("Premium consumer: Swanwick Sleep lenses"),
          item("More conventional frames and a current independent laboratory transmission report hosted by the company"),
          item("Higher cost; a transmission report verifies filtering, not treatment of insomnia"),
        ],
        [
          item("Premium prescription: custom amber lens from an optician"),
          item("Can address prescription, fit, side coverage, and a documented transmission target"),
          item("Most expensive and quality varies; ask for spectral data rather than a generic blue-light coating"),
        ],
      ),
      paragraph(
        "The ",
        link("2025 implementation review", SLEEP_HEALTH_SOURCES.blueGlassUtility2025.url),
        " notes that products sold as blue blockers differ dramatically. For circadian use, look for a transmission curve, meaningful attenuation through the blue and blue-green region, side coverage, and a tint dark enough to be visually obvious. A clear office lens designed for glare or comfort is not equivalent to an evening circadian filter.",
      ),
      paragraph(
        "Older ",
        link("Consumer Reports testing", SLEEP_HEALTH_SOURCES.uvexConsumerReports2017.url),
        " remains useful because it directly compared products and found the Uvex orange lens blocked much more blue light than lighter alternatives. Swanwick publishes ",
        link("current third-party laboratory reports", SLEEP_HEALTH_SOURCES.swanwickTransmission2026.url),
        ". Because that disclosure is hosted by the seller, verify that the report matches the exact lens being purchased.",
      ),
      heading("A better evening-light experiment"),
      ordered(
        item(strong("Get daytime light first. "), "A bright day supports a stronger day-night contrast; glasses cannot repair an entirely dim daytime routine."),
        item(strong("Pick a repeatable shutdown time. "), "Start with 30 minutes before intended sleep and move earlier only if the schedule and results justify it."),
        item(strong("Dim the room, not only the phone. "), "Overhead and bathroom lighting may reach the eyes more strongly than a dim display."),
        item(strong("Use a non-screen landing activity. "), "Write tomorrow's tasks, prepare the room, read print, stretch, or listen to calm audio."),
        item(strong("Track two weeks. "), "Note sleep onset, awakenings, wake time, and next-day function instead of judging one night."),
      ),
      paragraph(
        "Strong amber or red lenses distort color and reduce visual information. Do not drive or operate hazardous equipment in them. If screens are unavoidable, glasses are a light-control tool, not permission to keep doing the most activating possible activity until the second the lights go out.",
      ),
    ],
  },
  {
    slug: "z-drugs-zaleplon-zolpidem-eszopiclone",
    title: "Zaleplon vs Ambien and Other Z-Drugs for Insomnia",
    dek:
      "Zaleplon is the very short-acting Z-drug people often mean when they want less next-morning exposure. Its one-hour half-life fits sleep-onset difficulty, but it does not prove the second half of the night becomes normal.",
    seoDescription:
      "Compare zaleplon, zolpidem (Ambien), and eszopiclone by half-life, sleep-onset and maintenance effects, sleep quality, and FDA safety warnings.",
    focusPhrase: "zaleplon vs zolpidem Ambien",
    keywords: [
      "short half life sleep medication",
      "Sonata vs Ambien",
      "zaleplon half life",
      "Z-drugs sleep quality",
      "eszopiclone vs zolpidem",
    ],
    tags: ["sleep", "medications"],
    evidenceLabel: "Different duration profiles; small average benefits and serious risks",
    publishedAt: "2026-08-28",
    updatedAt: "2026-08-28",
    sourceIds: [
      "fdaZDrugs2019",
      "zaleplonLabel2019",
      "eszopicloneLabel2014",
      "hypnoticFdaMeta2012",
      "zDrugReview2012",
      "aasmPharmacologic2017",
      "cbtiGuideline2021",
    ],
    relatedSlugs: [
      "benadryl-diphenhydramine-for-sleep",
      "ghb-sodium-oxybate-and-sleep",
      "how-to-quiet-a-racing-mind-at-night",
    ],
    body: [
      callout(
        "The short answer",
        "The shorter-half-life Z-drug is zaleplon, sold historically as Sonata. Its elimination half-life is about one hour, compared with roughly two to three hours for immediate-release zolpidem and about six hours for eszopiclone. That makes zaleplon a sleep-onset drug more than a sleep-maintenance drug. It may reduce residual exposure, but the claim that it sedates only the first half and guarantees normal sleep afterward is a pharmacokinetic inference, not a demonstrated sleep-quality outcome.",
      ),
      heading("What Z-drugs are"),
      paragraph(
        "Zaleplon, zolpidem, and eszopiclone are prescription sedative-hypnotics that act at the benzodiazepine site of GABA-A receptors but have different chemistry and duration. “Non-benzodiazepine” does not mean non-sedating, non-habit-forming, or free from memory and coordination effects. They are controlled medicines intended for a clinician to match to a particular insomnia pattern and risk profile.",
      ),
      table(
        "The useful comparison is symptom window, not a winner",
        ["Medication", "Approximate elimination half-life", "What the profile tends to fit"],
        [
          item("Zaleplon"),
          item("About 1 hour"),
          item("Difficulty falling asleep; consistent benefits for awakenings or total duration were not established in the FDA label"),
        ],
        [
          item("Immediate-release zolpidem"),
          item("Often about 2–3 hours, with meaningful individual variation"),
          item("Sleep onset; controlled-release versions extend exposure for maintenance"),
        ],
        [
          item("Eszopiclone"),
          item("About 6 hours"),
          item("Sleep onset and maintenance, with more potential for next-day residual effects"),
        ],
      ),
      paragraph(
        "The ",
        link("zaleplon label", SLEEP_HEALTH_SOURCES.zaleplonLabel2019.url),
        " reports the approximately one-hour half-life and emphasizes sleep latency. It also says consistent improvements in sleep duration and number of awakenings were not demonstrated. The ",
        link("eszopiclone label", SLEEP_HEALTH_SOURCES.eszopicloneLabel2014.url),
        " describes a much longer half-life and next-day impairment concerns.",
      ),
      heading("Do Z-drugs produce lower-quality sleep?"),
      paragraph(
        "It is tempting to divide sleep into natural and drugged hours and assume a short half-life restores ordinary architecture as soon as blood levels fall. Sleep stages are dynamic, individual metabolism varies, active effects do not end at an exact stopwatch point, and insomnia itself changes architecture. The short-half-life logic is reasonable for reducing later exposure. It is not proof that the second half of the night is physiologically normal.",
      ),
      paragraph(
        "A ",
        link("review of sleep-medication pharmacology", SLEEP_HEALTH_SOURCES.zDrugReview2012.url),
        " describes generally subtle architecture effects and uncertain clinical significance. Some Z-drug studies report changes in slow-wave or REM measures; those results differ by drug, population, and protocol. Sleep quality also includes awakenings, next-day function, memory, and how the person feels, not only stage percentages.",
      ),
      heading("How large are the average benefits?"),
      paragraph(
        "A ",
        link("meta-analysis of FDA-submitted trials", SLEEP_HEALTH_SOURCES.hypnoticFdaMeta2012.url),
        " found statistically significant but generally small improvements, alongside a substantial placebo response. The AASM guideline offers weak, symptom-specific recommendations for several agents because evidence and trade-offs differ. Weak does not mean useless. It means preferences, risks, alternatives, and the exact sleep complaint matter.",
      ),
      heading("The risks that a half-life table hides"),
      paragraph(
        "The ",
        link("FDA Z-drug warning", SLEEP_HEALTH_SOURCES.fdaZDrugs2019.url),
        " highlights complex sleep behaviors such as sleepwalking, sleep-driving, cooking, and other actions while not fully awake. Serious injuries and deaths have occurred, sometimes after one use. Next-day impairment, falls, amnesia, unusual behavior, dependence, rebound insomnia, and dangerous interactions with alcohol, opioids, and other sedatives also matter.",
      ),
      unordered(
        item("A shorter half-life can reduce residual exposure but may provide less help for repeated awakenings."),
        item("A longer duration can support maintenance but can increase morning impairment."),
        item("Age, liver function, sex, other medicines, food, and formulation can change exposure."),
        item("No Z-drug should be combined casually with alcohol, opioids, GHB or oxybate, benzodiazepines, or other sleep products."),
      ),
      heading("A more useful clinician conversation"),
      paragraph(
        "Bring the actual pattern: time to fall asleep, number and timing of awakenings, early waking, opportunity for sleep, next-day driving, breathing symptoms, other substances, and prior complex sleep behaviors. Ask what measurable benefit would justify continuing and how the medicine will be reviewed. Do not borrow someone else's prescription or use a half-life chart to design middle-of-the-night dosing.",
      ),
      paragraph(
        "For chronic insomnia, CBT-I remains the first-line behavioral treatment with durable benefit after treatment ends. Medication can be appropriate in selected cases, including short-term support or a carefully reviewed adjunct. The right conclusion is not that zaleplon is the good Z-drug. It is that zaleplon is the shortest-acting common option, suited mainly to sleep-onset difficulty, with the same need for prescription oversight and safety boundaries.",
      ),
    ],
  },
  {
    slug: "ghb-sodium-oxybate-and-sleep",
    title: "GHB, Sodium Oxybate & Sleep Quality: Evidence and Risk",
    dek:
      "Prescription sodium oxybate has important uses in narcolepsy and idiopathic hypersomnia and can increase slow-wave sleep. That clinical evidence does not make illicit GHB a safe insomnia treatment.",
    seoDescription:
      "Review GHB and sodium oxybate sleep research, approved uses, slow-wave sleep findings, REMS controls, overdose risk, and limits of experience reports.",
    focusPhrase: "GHB sleep quality sodium oxybate",
    keywords: [
      "GHB for sleep",
      "sodium oxybate sleep quality",
      "Xyrem slow wave sleep",
      "GHB insomnia evidence",
      "GHB Erowid sleep reports",
    ],
    tags: ["sleep", "medications", "wellness-claims"],
    evidenceLabel: "Real clinical uses, profound CNS risk, not an insomnia shortcut",
    publishedAt: "2026-08-28",
    updatedAt: "2026-08-28",
    sourceIds: [
      "oxybateLabel2025",
      "oxybateNarcolepsyMeta2019",
      "oxybatePhysiological2012",
      "oxybateMdd2025",
      "oxybateHealthy2026",
      "erowidGhbOverdose",
      "erowidGhbWithdrawal",
      "erowidGhbVariable",
      "cbtiGuideline2021",
    ],
    relatedSlugs: [
      "z-drugs-zaleplon-zolpidem-eszopiclone",
      "kratom-after-no-sleep",
      "is-eight-hours-of-sleep-necessary",
    ],
    body: [
      callout(
        "The short answer",
        "GHB has been studied extensively as the prescription drug sodium oxybate. In restricted medical use it improves cataplexy and excessive daytime sleepiness in narcolepsy, and low-sodium oxybate is approved for idiopathic hypersomnia. It can increase slow-wave measures and consolidate disrupted sleep in those populations. It is not an ordinary insomnia medicine. The distance between an intended effect and respiratory depression, coma, or death can be dangerously small, especially with alcohol or other depressants, and pharmaceutical products are distributed through a REMS.",
      ),
      heading("The same molecule lives in very different systems"),
      paragraph(
        "Gamma-hydroxybutyrate is a central nervous system depressant. Sodium oxybate is a regulated pharmaceutical form manufactured, prescribed, dispensed, and monitored for defined indications. Illicit or informal GHB may have uncertain concentration, identity, co-ingredients, measuring tools, storage, and supervision. Evidence for one cannot be transferred to the other without carrying the controls with it.",
      ),
      paragraph(
        "The current ",
        link("FDA prescribing information and REMS", SLEEP_HEALTH_SOURCES.oxybateLabel2025.url),
        " covers sodium oxybate for cataplexy or excessive daytime sleepiness in narcolepsy and low-sodium oxybate for narcolepsy and adult idiopathic hypersomnia. The boxed warning addresses CNS depression and abuse or misuse. Respiratory depression, sleep-disordered breathing, confusion, depression, and dangerous interactions are explicit concerns.",
      ),
      heading("Why people describe the sleep as deep"),
      paragraph(
        "In narcolepsy, nighttime sleep is often fragmented. A ",
        link("15-trial systematic review", SLEEP_HEALTH_SOURCES.oxybateNarcolepsyMeta2019.url),
        " found improvements in cataplexy, daytime sleepiness, slow-wave sleep, awakenings, and reported nighttime quality, alongside more dose-related adverse effects than placebo. This is disease-specific evidence from clinical protocols, not a trial in ordinary stressed sleepers.",
      ),
      paragraph(
        "The phrase restorative slow-wave sleep also needs discipline. In a ",
        link("controlled physiology study", SLEEP_HEALTH_SOURCES.oxybatePhysiological2012.url),
        ", sodium oxybate increased low-frequency EEG power, but the researchers concluded that the induced slow waves did not appear functionally identical to physiological slow waves and did not improve measured performance or memory. More slow-wave-looking activity is not automatically better restoration.",
      ),
      table(
        "What different evidence streams can tell us",
        ["Evidence stream", "Useful conclusion", "What it cannot establish"],
        [
          item("Narcolepsy and hypersomnia trials"),
          item("Oxybate can improve specific disease symptoms under monitored pharmaceutical use"),
          item("Safety or benefit for unsupervised insomnia"),
        ],
        [
          item("Small experimental studies"),
          item("The drug can alter sleep architecture and next-day biology"),
          item("That every alteration is restorative or desirable"),
        ],
        [
          item("Experience reports"),
          item("Questions about short duration, redosing, dependence, withdrawal, and acute harm recur"),
          item("Frequency, causality, product identity, or a safe method"),
        ],
      ),
      heading("What newer experimental work adds"),
      paragraph(
        "A ",
        link("2025 crossover trial in major depressive disorder", SLEEP_HEALTH_SOURCES.oxybateMdd2025.url),
        " examined slow-wave sleep and next-day outcomes in a small clinical sample. A ",
        link("2026 healthy-volunteer study", SLEEP_HEALTH_SOURCES.oxybateHealthy2026.url),
        " found altered architecture and emotional-memory responses in 19 men. These studies show continuing pharmaceutical research. They do not establish GHB as a consumer sleep aid, and small mechanistic studies cannot define long-term benefit-risk.",
      ),
      heading("What Erowid and forum reports add, and what they do not"),
      paragraph(
        "Crowdsourced reports repeatedly describe a short, abrupt sleep period, waking and redosing, highly variable subjective restoration, rapid escalation, withdrawal insomnia, vomiting, unconsciousness, and emergency care. The ",
        link("overdose report", SLEEP_HEALTH_SOURCES.erowidGhbOverdose.url),
        ", ",
        link("withdrawal account", SLEEP_HEALTH_SOURCES.erowidGhbWithdrawal.url),
        ", and ",
        link("variable-sleep account", SLEEP_HEALTH_SOURCES.erowidGhbVariable.url),
        " are unverified narratives. They are useful because they expose failure modes that a simple “high-quality sleep” claim hides. They cannot establish prevalence, dose-response, purity, or effectiveness.",
      ),
      paragraph(
        "This article intentionally does not reproduce amounts or informal administration techniques. Concentration can vary, individual response is unpredictable, and turning an experience report into instructions would erase the most important finding: unsupervised use lacks the controls that make pharmaceutical research interpretable.",
      ),
      heading("Why mixing is especially dangerous"),
      unordered(
        item("Alcohol, opioids, benzodiazepines, Z-drugs, sedating antihistamines, kava, and other depressants can compound CNS and respiratory depression."),
        item("Sleep apnea or other breathing vulnerability can make a sedative's nighttime effects more dangerous."),
        item("A person who appears asleep may be severely intoxicated; inability to wake, abnormal breathing, seizure, or collapse requires emergency help."),
        item("Dependence can produce severe rebound and withdrawal symptoms that require medical care rather than improvised tapering."),
      ),
      heading("The clinical lesson"),
      paragraph(
        "GHB is not an example of a suppressed miracle sleep chemical. It is an example of a drug with real pharmacology, real approved uses, real sleep-stage effects, and a narrow enough safety context to require restricted distribution. Anyone with narcolepsy or idiopathic hypersomnia should discuss approved oxybate therapy with a sleep specialist. Anyone with chronic insomnia deserves evaluation and evidence-based care, not translation of a controlled-drug experience vault into a home protocol.",
      ),
    ],
  },
  {
    slug: "kratom-after-no-sleep",
    title: "Kratom After No Sleep? Why It Does Not Restore Sleep Loss",
    dek:
      "Kratom can feel stimulating or sedating, but no evidence shows that it reverses sleep-deprivation impairment. Dependence, withdrawal insomnia, contamination, and potent 7-OH products make it a risky morning-after strategy.",
    seoDescription:
      "Can kratom help after no sleep? Review stimulation, sleep disruption, dependence, withdrawal, 7-OH products, poison data, and safer recovery priorities.",
    focusPhrase: "kratom after no sleep",
    keywords: [
      "kratom for energy after no sleep",
      "kratom sleep deprivation",
      "kratom morning energy",
      "kratom affects sleep",
      "kratom withdrawal insomnia",
    ],
    tags: ["sleep", "medications", "wellness-claims"],
    evidenceLabel: "No restorative evidence and rising safety concerns",
    publishedAt: "2026-08-28",
    updatedAt: "2026-08-28",
    sourceIds: [
      "fdaKratom2026",
      "cdcKratom2026",
      "kratomWithdrawal2019",
      "kratomDependence2024",
      "kratomForum2026",
      "vanDongen2003",
      "aasmDurationConsensus2015",
    ],
    relatedSlugs: [
      "is-eight-hours-of-sleep-necessary",
      "ghb-sodium-oxybate-and-sleep",
      "morning-sunlight-and-sleep",
    ],
    body: [
      callout(
        "The short answer",
        "Kratom is not a proven way to restore the brain after a sleepless night. Some people report stimulant-like energy, while others report sedation, a later crash, poorer sleep, or withdrawal-related insomnia. Feeling more awake does not reverse impaired attention, judgment, or reaction time. Kratom products are not FDA-approved for this purpose, can produce dependence, and increasingly include concentrated or semisynthetic 7-hydroxymitragynine products with greater risk.",
      ),
      heading("Stimulation is not restoration"),
      paragraph(
        "After inadequate sleep, the immediate desire is often functional: stay awake, work, drive, or stop feeling miserable. A psychoactive substance can change the feeling of fatigue without repairing the missed sleep or reliably normalizing performance. This is the same distinction seen with caffeine, prescription stimulants, and other alerting drugs: subjective wakefulness and objective safety can separate.",
      ),
      paragraph(
        link(
          "Controlled sleep-restriction research",
          "https://pubmed.ncbi.nlm.nih.gov/12683469/",
        ),
        " shows that neurobehavioral performance can deteriorate cumulatively while subjective sleepiness fails to track the deficit accurately. No controlled kratom trial shows that the plant reverses those deficits.",
      ),
      paragraph(
        "Kratom, ",
        "Mitragyna speciosa",
        ", contains multiple alkaloids with complex and variable effects, including activity at opioid receptors. The ",
        link("FDA's current kratom page", SLEEP_HEALTH_SOURCES.fdaKratom2026.url),
        " says no kratom product is approved for a medical use and describes dependence, withdrawal, seizures, liver toxicity, and contamination concerns. “White,” “green,” and “red” strain labels are not standardized pharmacological categories and do not create an evidence-based morning protocol.",
      ),
      heading("What community reports reveal"),
      paragraph(
        "Crowdsourced discussions contain all of the expected directions: alertness and motivation, calm or sedation, delayed sleep, heavy morning grogginess, a rebound crash, waking in withdrawal, and difficulty sleeping after stopping. A ",
        link("recent community thread", SLEEP_HEALTH_SOURCES.kratomForum2026.url),
        " includes people describing later-day stimulation and the feeling of borrowing energy from the future. Other users report the opposite. These accounts are useful for identifying variation and failure modes. They cannot tell us which effect a new user will have or whether a product is what its label says.",
      ),
      table(
        "Why common kratom claims do not solve sleep loss",
        ["Claim", "What may be felt", "What remains unresolved"],
        [
          item("It gives morning energy"),
          item("Stimulant-like alertness or mood change"),
          item("No evidence of restored vigilance, judgment, memory, or safe driving"),
        ],
        [
          item("A red strain helps sleep"),
          item("Sedation in some users"),
          item("Strain labels are inconsistent; opioid-like effects, tolerance, and breathing risk remain"),
        ],
        [
          item("Plant powder is safer than extracts"),
          item("Lower concentration may reduce some acute risk"),
          item("Dependence, contamination, interactions, and product variation still occur"),
        ],
      ),
      heading("Dependence can create the sleep problem it appears to solve"),
      paragraph(
        "A ",
        link("systematic review of kratom withdrawal", SLEEP_HEALTH_SOURCES.kratomWithdrawal2019.url),
        " describes tolerance, dependence, and withdrawal, including sleep disruption. A ",
        link("2024 dependence study", SLEEP_HEALTH_SOURCES.kratomDependence2024.url),
        " found that physical dependence and use-disorder indicators became more likely as use frequency increased. The morning energy can therefore become relief from overnight withdrawal rather than recovery from the original poor sleep.",
      ),
      heading("The product market is becoming more hazardous"),
      paragraph(
        "The ",
        link("2026 CDC poison-center analysis", SLEEP_HEALTH_SOURCES.cdcKratom2026.url),
        " found approximately a 1,200 percent increase in kratom-related exposure reports from 2015 to 2025, with a sharp rise in 2025 and concern about high-potency alkaloid products. Multiple-substance reports had more hospitalizations and serious outcomes and accounted for most associated deaths in the dataset. Poison-center reports do not measure total use or individual probability, but the trend argues against casual safety claims.",
      ),
      paragraph(
        "Concentrated 7-OH and semisynthetic products deserve special separation from traditional leaf material. They can be sold with candy-like branding or as enhanced kratom while delivering a different potency profile. Avoiding those products does not make ordinary kratom restorative; it only removes one escalating risk.",
      ),
      heading("What to prioritize after a bad night"),
      ordered(
        item(strong("Protect safety. "), "Do not drive or perform hazardous work if you are fighting sleep or having attention lapses. Alerting feelings are not a clearance test."),
        item(strong("Use light and timing. "), "Get ordinary daytime light, keep a reasonable wake schedule, and avoid turning one bad night into a full circadian reversal."),
        item(strong("Use naps deliberately. "), "A short planned nap can help some people, while a long late nap can reduce the next night's sleep pressure."),
        item(strong("Reduce the next night's obstacles. "), "Avoid stacking sedatives or stimulants, and return to a calm, repeatable wind-down."),
        item(strong("Look for the pattern. "), "Repeated all-night insomnia, breathing symptoms, mood elevation, substance withdrawal, or disabling sleepiness deserves qualified evaluation."),
      ),
      paragraph(
        "This is not a moral judgment about people who use kratom for pain or opioid withdrawal. Those are complex clinical and public-health contexts. It is a narrower conclusion: no controlled evidence supports kratom as restoration after sleep loss, and the known risks make it a poor experiment for an already impaired person.",
      ),
    ],
  },
  {
    slug: "how-to-quiet-a-racing-mind-at-night",
    title: "How to Quiet a Racing Mind at Night",
    dek:
      "The goal is not to force thoughts away. Offload specific tasks, give worries a next action, stop clock-checking, and reduce the struggle around sleep. These techniques fit the cognitive logic of CBT-I.",
    seoDescription:
      "Learn evidence-based ways to quiet a racing mind at night: a bedtime to-do list, constructive worry, scheduled next steps, stimulus control, and CBT-I.",
    focusPhrase: "how to quiet a racing mind at night",
    keywords: [
      "can't turn off brain at night",
      "racing thoughts insomnia",
      "write to do list before bed",
      "constructive worry sleep",
      "how to stop thinking and sleep",
    ],
    tags: ["sleep", "behavior"],
    evidenceLabel: "Small direct trials plus strong CBT-I principles",
    publishedAt: "2026-08-28",
    updatedAt: "2026-08-28",
    sourceIds: [
      "toDoList2018",
      "constructiveWorry2006",
      "clockMonitoring2006",
      "cognitiveReview2024",
      "mindfulnessMeta2022",
      "cbtiGuideline2021",
      "screenRestriction2020",
    ],
    relatedSlugs: [
      "screens-blue-light-glasses-and-sleep",
      "benadryl-diphenhydramine-for-sleep",
      "why-you-sleep-badly-in-hotels",
    ],
    body: [
      callout(
        "The short answer",
        "A racing mind often persists because the brain is trying to remember, solve, monitor, or prevent something. The most useful first move is not “stop thinking.” It is to externalize each open loop: write the specific task or worry, assign the smallest next action, and put it on tomorrow's list or calendar. Then leave the bed if wakeful struggle continues, stop checking the time, and return only when sleepy. A five-minute bedtime to-do-list study and constructive-worry research support parts of this approach, while CBT-I provides the stronger clinical framework.",
      ),
      heading("Why forcing the mind off usually backfires"),
      paragraph(
        "Sleep is a state that arrives under the right conditions, not a performance that improves with effort. Monitoring whether you are asleep, calculating tomorrow's damage, and commanding yourself to relax all increase attention to the problem. A ",
        link("systematic review of cognitive factors", SLEEP_HEALTH_SOURCES.cognitiveReview2024.url),
        " maps worry, rumination, threat monitoring, dysfunctional beliefs, and sleep effort as overlapping processes rather than one generic overactive brain.",
      ),
      heading("The evidence for writing tomorrow down"),
      paragraph(
        "In a ",
        link("one-night laboratory study", SLEEP_HEALTH_SOURCES.toDoList2018.url),
        ", 57 healthy adults spent five minutes writing either future tasks or completed tasks before bed. The future to-do group fell asleep faster on polysomnography, and more specific lists were associated with faster onset. It was a small, young sample in a lab, not a chronic-insomnia treatment trial, but it directly tests the open-loop idea.",
      ),
      paragraph(
        "A ",
        link("constructive-worry study", SLEEP_HEALTH_SOURCES.constructiveWorry2006.url),
        " asked college students with insomnia to list worries and write a next step for each before bed. Pre-sleep cognitive arousal decreased over the following nights. The useful ingredient may be closure: the worry has been acknowledged and given a place to continue.",
      ),
      heading("A ten-minute shutdown sequence"),
      ordered(
        item(strong("Capture every open loop. "), "Write concrete nouns and verbs: “email Dana the revised budget,” not “fix life.”"),
        item(strong("Choose the next visible action. "), "If a task is too large, name the first step that can actually happen tomorrow."),
        item(strong("Assign a trusted home. "), "Put it on a dated list, schedule a short calendar block, or identify the person and time needed."),
        item(strong("Separate solvable from uncontrollable. "), "For a solvable worry, write the next action. For an uncontrollable one, write what support or boundary is available."),
        item(strong("Close the list. "), "Use one sentence: “This is captured; I am not required to solve it in bed.” Then move to a low-stimulation activity."),
      ),
      paragraph(
        "Scheduling a calendar event is a practical extension of the writing studies, not a directly proven special ingredient. It can strengthen trust in the capture system because the concern now has a time and duration. The calendar should contain a realistic next step, not a midnight promise to complete an impossible backlog tomorrow.",
      ),
      heading("Do not turn the notebook into another feed"),
      paragraph(
        "Keep the capture tool boring. Paper is ideal for many people. If a phone is necessary, use one local note, dim it, disable notifications, and stop after capture. A ",
        link("small phone-restriction trial", SLEEP_HEALTH_SOURCES.screenRestriction2020.url),
        " found benefits when participants stopped phone use 30 minutes before bed, though it could not separate light from arousal or time displacement.",
      ),
      heading("Stop clock-checking"),
      paragraph(
        "In an ",
        link("experimental clock-monitoring study", SLEEP_HEALTH_SOURCES.clockMonitoring2006.url),
        ", access to the clock increased worry and perceived sleep-onset difficulty. Turning the clock away removes a repeated threat cue. You do not need minute-by-minute data to know that the night is difficult, and repeated calculations rarely produce a useful action at 2:17 a.m.",
      ),
      heading("Use stimulus control when the bed becomes a thinking desk"),
      paragraph(
        "The AASM behavioral guideline gives multicomponent CBT-I a strong recommendation and conditionally supports stimulus control, sleep restriction therapy, and relaxation therapy. Stimulus control aims to restore the association between bed and sleep: go to bed when sleepy, use the bed for sleep and intimacy, and leave for a quiet dim place when wakeful struggle continues, returning when sleepiness returns.",
      ),
      table(
        "Match the mental pattern to the tool",
        ["Pattern", "Better first tool", "Why"],
        [
          item("Remembering tasks"),
          item("Specific to-do list plus calendar slot"),
          item("Moves memory responsibility into a trusted external system"),
        ],
        [
          item("Problem-solving a worry"),
          item("Constructive worry: concern plus next action"),
          item("Creates bounded closure without pretending the issue is solved"),
        ],
        [
          item("Checking whether sleep is happening"),
          item("Hide the clock and reduce sleep tracking"),
          item("Removes performance monitoring and threat calculations"),
        ],
        [
          item("Hours of wakeful struggle in bed"),
          item("Stimulus control within a CBT-I plan"),
          item("Weakens the learned bed-equals-alertness association"),
        ],
      ),
      heading("Where relaxation and mindfulness fit"),
      paragraph(
        "Slow breathing, progressive muscle relaxation, guided imagery, and mindfulness can reduce arousal. They work poorly when used as a desperate test that must knock you out immediately. An ",
        link("updated mindfulness meta-analysis", SLEEP_HEALTH_SOURCES.mindfulnessMeta2022.url),
        " found mixed effects and does not support mindfulness alone as a universal substitute for CBT-I. Practice the technique as a way to change the relationship to wakefulness, not as an off switch.",
      ),
      heading("When a racing mind needs more than a trick"),
      paragraph(
        "Persistent insomnia, panic, trauma symptoms, depression, substance withdrawal, ADHD, and periods of unusually elevated mood can all present as an overactive mind but require different care. Several nights with little need for sleep, increasing energy, impulsivity, or unusual confidence can be urgent. Loud snoring, gasping, restless legs, pain, or medication effects can also keep the brain alert because the body is repeatedly disturbed.",
      ),
      paragraph(
        "For ordinary open loops, the method is simple: capture, clarify, schedule, and release. For chronic insomnia, use those tools inside a structured CBT-I approach rather than building an ever-larger collection of bedtime hacks.",
      ),
    ],
  },
] as const;
